Patents by Inventor Peter Turecek

Peter Turecek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FACTOR VIII POLYMER CONJUGATES
    Publication number: 20110112028
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
    Type: Application
    Filed: January 20, 2011
    Publication date: May 12, 2011
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann
  • FACTOR VIII POLYMER CONJUGATES
    Publication number: 20110112026
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
    Type: Application
    Filed: January 20, 2011
    Publication date: May 12, 2011
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann
  • FACTOR VIII POLYMER CONJUGATES
    Publication number: 20110112024
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
    Type: Application
    Filed: January 20, 2011
    Publication date: May 12, 2011
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann
  • Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
    Publication number: 20110072524
    Abstract: The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand Factor, and methods to treat hereditary or acquired hemophilia A or von Willebrand Disease (VWD) by administration of exogenous human VWF.
    Type: Application
    Filed: August 4, 2010
    Publication date: March 24, 2011
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Peter Turecek, Raffi Udin Ahmad, Herbert Gritsch, Eva-Maria Muchitsch, Hans-Peter Schwarz
  • Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 7910094
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: March 22, 2011
    Assignee: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Polymer-factor VIII-von Willebrand factor-conjugates
    Patent number: 7884075
    Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: February 8, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann
  • BLOOD COAGULATION PROTEIN CONJUGATES
    Publication number: 20110028693
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.
    Type: Application
    Filed: July 26, 2010
    Publication date: February 3, 2011
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: JUERGEN SIEKMANN, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS
    Publication number: 20110027350
    Abstract: A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.
    Type: Application
    Filed: July 26, 2010
    Publication date: February 3, 2011
    Applicants: LIPOXEN TECHNOLOGIES LIMITED, BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA
    Inventors: Sanjay Jain, Gregory Gregoriadis, Archana Dwivedi, Srijit Nath, Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Method for the purification of alpha-1 proteinase inhibitor (a1PI)
    Patent number: 7807435
    Abstract: The present invention relates to a method for the purification of alpha-1 proteinase inhibitor (a1PI) from protein fractions. More specifically, the invention relates to an improved method for the purification of alpha-1 proteinase inhibitor (a1PI), wherein the yield of a1PI can be increased by thawing the starting material and incubating it for several hours before subjecting it to a washing step.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: October 5, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Matthiessen, Gerald Brachtl, Peter Turecek, Hans-Peter Schwarz
  • FACTOR VIII POLYMER CONJUGATES
    Publication number: 20100173831
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
    Type: Application
    Filed: January 8, 2010
    Publication date: July 8, 2010
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann
  • FACTOR VIII POLYMER CONJUGATES
    Publication number: 20100173830
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
    Type: Application
    Filed: January 8, 2010
    Publication date: July 8, 2010
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: PETER TURECEK, Juergen Siekmann
  • Pegylated Factor VIII
    Publication number: 20100168391
    Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.
    Type: Application
    Filed: March 8, 2010
    Publication date: July 1, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek
  • RECOMBINANT VON WILLEBRAND FACTOR AS MOLECULAR WEIGHT MARKER FOR MASS SPECTROMETRY ANALYSES
    Publication number: 20100155588
    Abstract: Methods for determining molecular mass of at least 150 kDa of an analyte of interest using MALDI mass spectrometry in combination with a recombinant von Willebrand factor (rVWF) molecular weight marker are disclosed. More specifically, monomeric and multimeric rVWF are used for external and internal calibration of mass spectra applied for analytes having high molecular weights above 150 kDa.
    Type: Application
    Filed: December 16, 2009
    Publication date: June 24, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A., TECHNISCHE UNIVERSITAET WIEN
    Inventors: Jasmin Kemptner, Martina Marchetti-Deschmann, Roland Mueller, Andreas Ivens, Peter Turecek, Hans-Peter Schwarz, Guenter Allmaier
  • DETECTION OF PHYSIOLOGICALLY ACCEPTABLE POLYMER MOLECULES USING NEAR INFRARED SPECTROSCOPY
    Publication number: 20100152115
    Abstract: The present invention relates, in general, to methods for detecting the amount of a polymer on a protein using near-infrared spectroscopy. Measurement of the number of polymer moieties per protein molecule allows for production of molecules having a uniform number of polymer moieties, which is useful in the production of pharmaceutical compositions.
    Type: Application
    Filed: December 11, 2009
    Publication date: June 17, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Alfred Weber, Joris Hoefinghoff, Juergen Siekmann, Peter Turecek
  • METHODS OF MEASURING ADAMTS13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF
    Publication number: 20100143957
    Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
    Type: Application
    Filed: December 3, 2009
    Publication date: June 10, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
  • METHODS OF DETERMINING POLYDISPERSITY AND/OR MOLECULAR WEIGHT DISTRIBUTION OF A POLYETHYLENE GLYCOL SAMPLE
    Publication number: 20100126866
    Abstract: Disclosed herein are methods of determining polydispersity (PDI) and molecular mass distribution (MMD) of reactive PEG samples using mass spectrometry. More specifically, a mass spectrometry method called GEMMA is used to determine PDI and MMD of PEG samples which provides more accurate measurements for high molecular weight PEG samples than prior known MALDI-TOF analysis.
    Type: Application
    Filed: November 18, 2009
    Publication date: May 27, 2010
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC., TECHNISCHE UNIVERSITAET WIEN
    Inventors: Jasmin Kemptner, Martina Marchetti-Deschmann, Juergen Siekmann, Peter Turecek, Hans-Peter Schwarz, Guenter Allmaier
  • Hydrolysable Polymeric FMOC-Linker
    Publication number: 20100121034
    Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.
    Type: Application
    Filed: January 15, 2010
    Publication date: May 13, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Peter Turecek, Juergen Siekmann
  • Hydrolysable Polymeric FMOC- Linker
    Publication number: 20100121028
    Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.
    Type: Application
    Filed: January 18, 2010
    Publication date: May 13, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Peter Turecek, Juergen Siekmann
  • Method for preparing Fmoc-based hydrolysable linkers
    Patent number: 7714147
    Abstract: A novel process for the production of Fmoc (9H-fluoren-9-ylmethoxycarbonyl)-based compounds is provided, wherein a protecting group for the 9-hydroxymethyl group of the fluorene ring system is utilized. These compounds are useful for the modification of protein and peptide drugs.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: May 11, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter Turecek, Juergen Siekmann, Christian Noe, Gerhard Stoiber
  • METHODS FOR DETERMINING ACTIVE INGREDIENTS IN PRO-DRUG PEG PROTEIN CONJUGATES WITH RELEASABLE PEG REAGENTS (IN VITRO DE-PEGYLATION)
    Publication number: 20100112607
    Abstract: The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.
    Type: Application
    Filed: October 20, 2009
    Publication date: May 6, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A., NEKTAR THERAPEUTICS
    Inventors: Katalin Varadi, Gerald Schrenk, Hanspeter Rottensteiner, Peter Turecek, Alfred Weber, Heinz Anderle, Sean M. Culbertson, Zhihao Fang, Harold Zappe, Ping Zhang, Mary J. Bossard